Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

This publication has 48 references indexed in Scilit:

• 2012 focused update of the ESC Guidelines for the management of atrial fibrillation
  European Heart Journal, 2012
• New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes
  JACC, 2012
• New Frontiers for Stroke Prevention in Atrial Fibrillation
  Cerebrovascular Diseases, 2012
• Apixaban versus Warfarin in Patients with Atrial Fibrillation
  New England Journal of Medicine, 2011
• Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
  New England Journal of Medicine, 2011
• Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review
  The American Journal of Medicine, 2010
• Dabigatran versus Warfarin in Patients with Atrial Fibrillation
  New England Journal of Medicine, 2009
• Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation
  Annals of Internal Medicine, 2007
• An Introduction to Markov Modelling for Economic Evaluation
  PharmacoEconomics, 1998
• Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.
  Stroke, 1991